EUVIMEDEUVIMED entdecken
Open Access · CC0

Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens

Rolando D Z Lyles iD, Maria J Martinez, Benjamin Sherman, Stephan Schürer, Kerry L Burnstein iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0287126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Rolando D Z Lyles und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida, United States of America. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Florida Department of Health, The Mike Slive Foundation, Sylvester Comprehensive Cancer Center, University of Miami Health Systems.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen deprivation therapy (ADT) is the standard of care for high risk and advanced prostate cancer; however, disease progression from androgen-dependent prostate cancer (ADPC) to lethal and incurable castration-resistant prostate cancer (CRPC) and (in a substantial minority of cases) neuroendocrine prostate cancer (NEPC) is common. Identifying effective targeted therapies is challenging because of acquired resistance to established treatments and the vast heterogeneity of advanced prostate cancer (PC). To streamline the identification of potentially active prostate cancer therapeutics, we have developed an adaptable semi-automated protocol which optimizes cell growth and leverages automation to enhance robustness, reproducibility, and throughput while integrating live-cell imaging and endpoint viability assays to assess drug efficacy in vitro. In this study, culture conditions for 72-hr drug screens in 96-well plates were established for a large, representative panel of human prostate cell lines including: BPH-1 and RWPE-1 (non-tumorigenic), LNCaP and VCaP (ADPC), C4-2B and 22Rv1 (CRPC), DU 145 and PC3 (androgen receptor-null CRPC), and NCI-H660 (NEPC). The cell growth and 72-hr confluence for each cell line was optimized for real-time imaging and endpoint viability assays prior to screening for novel or repurposed drugs as proof of protocol validity. We demonstrated effectiveness and reliability of this pipeline through validation of the established finding that the first-in-class BET and CBP/p300 dual inhibitor EP-31670 is an effective compound in reducing ADPC and CRPC cell growth. In addition, we found that insulin-like growth factor-1 receptor (IGF-1R) inhibitor linsitinib is a potential pharmacological agent against highly lethal and drug-resistant NEPC NCI-H660 cells. This protocol can be employed across other cancer types and represents an adaptable strategy to optimize assay-specific cell growth conditions and simultaneously assess drug efficacy across multiple cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansAndrogensReproducibility of ResultsAndrogen AntagonistsCell SurvivalCell Line, TumorReceptors, AndrogenAutomation

Substanzen

AndrogensAndrogen AntagonistsReceptors, Androgen

Autor:innen und Institutionen

  • Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
  • Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States of America.
  • Department of Molecular & Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, United States of America.

ORCID-Profile: Rolando D Z Lyles, Kerry L Burnstein

Förderung

  • Florida Department of Health
  • The Mike Slive Foundation
  • Sylvester Comprehensive Cancer Center, University of Miami Health Systems

Zitieren

APA

Lyles, R. D. Z., Martinez, M. J., Sherman, B., Schürer, S., & Burnstein, K. L. (2023). Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. PLOS ONE. https://doi.org/10.1371/journal.pone.0287126

Vancouver

Lyles RDZ, Martinez MJ, Sherman B, Schürer S, Burnstein KL. Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens. PLOS ONE. 2023. doi:10.1371/journal.pone.0287126

BibTeX
@article{Lyles2023,
  author = {Lyles, Rolando D Z and Martinez, Maria J and Sherman, Benjamin and Schürer, Stephan and Burnstein, Kerry L},
  title = {Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0287126}
}
Kostenlos starten →